Martin O’Dea on Biomarkers, Longevity Innovation & the Future of Aging Science

As the longevity field advances, biomarkers have become the key to validating interventions and driving real progress. Without measurable indicators, clinical trials remain impractical, regulatory approvals stagnate, and public trust in longevity therapies remains uncertain.

In my latest conversation with Martin O’Dea, we explore the evolving role of biomarkers in aging science, from the promise of epigenetic clocks and proteomics to the emerging biomarker standardization efforts shaping longevity clinics and research.